Maviret

Glecaprevir/pibrentasvir, the active ingredient in Maviret, is a direct‑acting antiviral presented as a 300 mg/120 mg tablet for oral use. Approved in the European Union, it treats chronic hepatitis C virus infection across genotypes 1‑6 in adult patients.

GNH USA supplies Maviret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance, and timely delivery, with a global network that supports procurement and logistics for complex therapeutic agents.

Maviret is a direct‑acting antiviral indicated for chronic hepatitis C virus infection in adults.

Chronic hepatitis C virus infection (genotypes 1‑6): achieves sustained virologic response, effectively clearing the virus.

Maviret may cause adverse reactions; reported events are categorized by frequency.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Headache: mild to moderate head pain. - Nausea: sensation of unease in the stomach. - Diarrhea: loose or watery stools. - Pruritus: itching of the skin. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Elevated liver enzymes: indication of liver stress. - Hepatic decompensation: worsening liver function. - Severe rash or allergic reaction: skin eruptions, swelling, or breathing difficulty. - Anemia: reduced red blood cell count. - Thrombocytopenia: low platelet count increasing bleeding risk.

When prescribing Maviret, consider the following precautions to optimize safety.

Assess liver function: evaluate hepatic status before initiating therapy. Monitor hepatic enzymes: regular testing during treatment. Avoid in severe hepatic impairment: contraindicated in Child‑Pugh class C patients. Use caution in pregnancy: limited data, weigh benefits against risks. Evaluate renal function: adjust use if significant renal impairment exists. Store at below 25°C: keep in the original pack, protect from moisture.

Maviret has potential drug‑drug interactions that require clinical attention.

Major Interactions (Avoid): - Rifampin: strong CYP3A inducer that reduces exposure. - Carbamazepine: potent enzyme inducer diminishing efficacy. - St. John’s wort: herbal CYP3A inducer that may lower drug levels.

Moderate Interactions (Monitor Closely): - Efavirenz: moderate CYP3A inducer, may require monitoring. - Omeprazole and other PPIs: can decrease pibrentasvir absorption. - Simvastatin: increased statin exposure, risk of myopathy.